Bioorganic and Medicinal Chemistry Letters p. 2210 - 2214 (2010)
Update date:2022-08-04
Topics:
Dong, Liming
Marakovits, Joseph
Hou, Xinjun
Guo, Chuangxing
Greasley, Samantha
Dagostino, Eleanor
Ferre, RoseAnn
Johnson, M. Catherine
Kraynov, Eugenia
Thomson, James
Pathak, Ved
Murray, Brion W.
Following the discovery of a novel series of phosphate-containing small molecular Pin1 inhibitors, the drug design strategy shifted to replacement of the phosphate group with an isostere with potential better pharmaceutical properties. The initial loss in potency of carboxylate analogs was likely due to weaker charge-charge interactions in the putative phosphate binding pocket and was subsequently recovered by structure-based optimization of ligand-protein interactions in the proline binding site, leading to the discovery of a sub-micromolar non-phosphate small molecular Pin1 inhibitor.
View MoreSynchem Pharma Co.,Ltd(expird)
Contact:+0086-21-61984905-1
Address:Building 60,Zimian Park, LongYang industrial Area, 1515Nong,Yuandong Road Fengxian District, Shanghai ,China
Zipont chem(wuhan)Tech co.,Ltd
Contact:+86-27-87587198
Address:wuhan
Contact:0512-63006287
Address:no.88.YISHENG Road,etdz-WUJIANG,SUZHOU,CHINA
Tianjin Pharmacn Medical Technology Co.,Ltd.
Contact:86-22-60122566ext.866(English),23359620
Address:Green Industrial Base, 6 Haitaifazhan Sixth Rd., Huayuan Industrial Area, Tianjin, 300384, China
Contact:+86-571-28186845
Address:Room 1224,Eastcom Mansion,398 Wensan Road,Hangzhou,310013 China
Doi:10.1080/15421400902841445
(2009)Doi:10.1016/j.jorganchem.2017.09.020
(2018)Doi:10.1016/j.tetlet.2010.02.120
(2010)Doi:10.1080/00397911.2016.1139723
(2016)Doi:10.1021/ja1031024
(2010)Doi:10.1139/v82-425
(1982)